AMRN — AMARIN CORP PLC\UK
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 897448 ·
Ireland
Last close
$14.26
Market Cap
$299.02M
52W High
$17.25
52W Low
$12.96
ADV30
77,120
Next earnings
2026-10-28
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 42,211,000 | 14,989,000 | -11,970,000 | -7,650,000 | 624,363,000 | 143,558,000 | 180,747,000 |
| Mar 2026 | 45,132,000 | 17,769,000 | -8,011,000 | -10,512,000 | 645,764,000 | 131,063,000 | 196,351,000 |
| Dec 2025 | 49,219,000 | 23,169,000 | -2,261,000 | -1,224,000 | 670,775,000 | 134,660,000 | 211,494,000 |
| Sep 2025 | 49,670,000 | 22,208,000 | -1,697,000 | -7,738,000 | 659,814,000 | 122,802,000 | 200,920,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$15,573,000
Investing CF
$-17,805,000
Financing CF
$-2,186,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.40
As of
2026-08-02
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,717,856,000
Inventory
$183,585,000
Receivables
$108,051,000
ST Investments
$176,759,000
EBIT TTM
$-27,295,000
Pretax Income TTM
$-31,140,000
Interest Exp TTM
—
Analysts
2
Yahoo Snapshot (yfinance, live)
Total Revenue
$186,232,992
EBITDA
$-21,094,000
Free Cash Flow
$2,224,500
Enterprise Value
$-12,469,428
Total Cash
$314,648,992
Total Debt
$5,255,000
Shares Out
20,969,109
Trailing EPS
$-1.20
Book Value
$21.30
ROE
-6.0%
ROA
-2.3%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 213,646,000 | -13,941,000 | -38,798,000 | 670,775,000 | 211,494,000 | — | 6,728,000 |
| Dec 2024 | 228,614,000 | -91,797,000 | -82,183,000 | 685,349,000 | 199,173,000 | — | -31,020,000 |
| Dec 2023 | 306,911,000 | -56,616,000 | -59,112,000 | 831,684,000 | 279,587,000 | — | 6,880,000 |
| Dec 2022 | 369,193,000 | -92,343,000 | -105,803,000 | 886,179,000 | 290,846,000 | — | -180,092,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$0.98
Max Pain — expiry 2026-08-21
max pain strike: $14.00 · spot: $14.26 · call oi: 636 · put oi: 542
Expected Move to 2026-08-21:
±$1.77
(12.45%) —
implied range
$12.49 –
$16.04
· ATM straddle on $14.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| PRLD | Prelude Therapeutics Inc | $298.62M | $4.60 | — |
| LYEL | Lyell Immunopharma, Inc. | $301.94M | $12.94 | — |
| ORGO | Organogenesis Holdings Inc. | $304.96M | $2.37 | — |
| IRD | Opus Genetics, Inc. | $306.32M | $3.71 | — |
| VNDA | Vanda Pharmaceuticals Inc. | $306.69M | $5.10 | — |
News headlines (Yahoo Finance, 1h cache)
Amarin Corp PLC (AMRN) Q2 2026 Earnings Call Highlights: Strategic Growth Amidst Revenue Challenges
2026-07-29 19:03 · Yahoo
Amarin's Q2 Earnings Beat Estimates, Revenues Fall Short
2026-07-29 16:17 · Yahoo
European Equities Traded in US as ADRs Ease in Wednesday Trading
2026-07-29 15:05 · Yahoo
Amarin Reports Second-Quarter Results as Partnered International Strategy Gains Momentum
2026-07-29 14:42 · Yahoo
Amarin Q2 Earnings Call Highlights
2026-07-29 13:03 · Yahoo
Amarin Reports 2026 Second Quarter Financial Results Demonstrating Early Success of Fully Partnered International Commercial Strategy and Continued Leading U.S. Market Presence
2026-07-29 11:00 · Yahoo
AGIO Shares Sink Nearly 7% After Scrapping the Tebapivat SCD Program
2026-07-22 16:22 · Yahoo
Here's Why You Should Add Savara Stock to Your Portfolio Now
2026-07-22 13:21 · Yahoo
Acadia Gets FDA's Fast Track Tag for Alzheimer's Disease Candidate
2026-07-21 14:47 · Yahoo
DYN Stock Rises 19.2% in 3 Months: What's Driving the Rally?
2026-07-21 14:20 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.